



# SARS-CoV-2-induced senescence as a potential therapeutic target

Mary Denholm <sup>1,2</sup>, Robert C. Rintoul <sup>3,4</sup> and Daniel Muñoz-Espín <sup>1,4</sup>

<sup>1</sup>Early Cancer Institute, Dept of Oncology, University of Cambridge, Cambridge, UK. <sup>2</sup>Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. <sup>3</sup>Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. <sup>4</sup>Cancer Research UK Cambridge Centre Thoracic Cancer Programme, Cambridge, UK.

Corresponding author: Daniel Muñoz-Espín ([dm742@cam.ac.uk](mailto:dm742@cam.ac.uk))



Shareable abstract (@ERSpublications)

Long implicated in the pathology of ageing, cancer and many other systemic diseases, cellular senescence is now emerging as a key factor in the pathogenesis of severe COVID-19, with implications for other viral illnesses. <https://bit.ly/3bbmOuT>

**Cite this article as:** Denholm M, Rintoul RC, Muñoz-Espín D. SARS-CoV-2-induced senescence as a potential therapeutic target. *Eur Respir J* 2022; 60: 2201101 [DOI: 10.1183/13993003.01101-2022].

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 27 May 2022  
Accepted: 17 June 2022

The global coronavirus disease 2019 (COVID-19) pandemic has caused major morbidity, mortality and socioeconomic disruption on an individual and collective level. Over 6 million COVID-19-related deaths have been reported, with total case numbers now well over 500 million worldwide [1]. Whilst the prompt and efficient design of effective vaccines has restored varying degrees of normal activity to some parts of world, the effects of the pandemic will be long in duration and far-reaching.

Our knowledge of the mechanisms of action of the pandemic's causative agent, the human pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has progressed at great speed since the onset of the pandemic, with resultant implications for clinical care and vaccination strategies. In this issue of the *European Respiratory Journal*, EVANGELOU *et al.* [2] outline the role of cellular senescence in the pathogenesis of severe clinical forms of COVID-19.

Cellular senescence is a state of stable and generally irreversible cell cycle arrest characterised by altered cell morphology and metabolism, in conjunction with generation of a potent secretory pro-inflammatory environment, the senescence-associated secretory phenotype (SASP) [3]. Originally identified in the setting of replicative senescence, whereby cultured cells cease to replicate after a set number of cell divisions [4], senescence has since been found to arise in response to a wide number of stressors, including oncogene activation, genotoxic stress and hypoxia among others [3]. This expansion in the understanding of senescence has led to it being widely implicated in a range of diseases, including cancer, fibrosis, neurodegenerative diseases and atherosclerosis among many others [5]. Its role in diseases of ageing and how it may contribute to the frailty, multi-morbidity and enhanced clinical vulnerabilities seen in older populations is an area of increasing focus [6], including within this pandemic [7].

Virus-induced senescence is less well understood than other senescence-inducing mechanisms, but as recently summarised by KOHLI *et al.* [8], senescence may be induced both in response to viruses themselves, as an antiviral defence mechanism, and in response to antiviral therapies [8, 9]. To date, the most significant exploration in this area has related to HIV, where senescence has been implicated as a potentially detrimental outcome of anti-retroviral therapy, contributing to premature ageing phenotypes [8, 10, 11] and, as recently summarised by SÁNCHEZ-DÍAZ *et al.* [12], a number of senolytic and senomorphic agents are being investigated in this setting.

In their study, EVANGELOU *et al.* [2] used autopsy lung tissue samples from COVID-19 patients to establish the presence of senescence and demonstrate evidence of increased expression of the key SASP cytokines, interleukin (IL)-1 $\beta$  and IL-6. These findings provide a link for how virus-induced senescence and the



SASP can be implicated in the cytokine storm and immune activation that characterises severe clinical forms of COVID-19, which feature significant mortality rates and a wide range of systemic complications causing notable morbidity for those patients that survive [13, 14]. IL-6 has already been in particular focus within the pandemic, including as a therapeutic target with the use of the monoclonal antibody tocilizumab, which is recommended as a treatment option in certain sets of hospitalised patients based on the results of a number of clinical trials [15]. As a comparison, EVANGELOU *et al.* [2] describe that SARS-CoV-2-infected alveolar type 2 (AT2) cells from the lungs of patients with severe COVID-19 displayed significantly higher levels of senescence than those of an age-matched control group including patients with acute pneumonia and other respiratory pathologies.

Particularly noteworthy given the multi-system nature of COVID-19, EVANGELOU *et al.* [2] also demonstrate the presence of senescence in extrapulmonary sites including the kidneys and liver. They correlate their findings *in vitro* by demonstrating the establishment of senescence in Vero-E6 epithelial kidney cells infected with SARS-CoV-2, with dramatically reduced implementation of senescence in response to treatment with a selective ataxia-telangiectasia-mutated (ATM) inhibitor, strongly suggesting DNA damage as an initiator of senescence in this setting. Interestingly, TSUJI *et al.* [16] recently proposed virus-induced cytokine production as an inducer of senescence in COVID-19 infections, having demonstrated that human lung diploid fibroblasts infected with SARS-CoV-2 can induce a senescent-like phenotype in neighbouring uninfected cells. The senescent cells then continue to express high levels of SASP factors even once SARS-CoV-2 infection is no longer detectable, a finding corroborated by re-analysis of single-cell transcriptomic data from lung tissue of patients with severe and prolonged COVID-19 [17]. TSUJI *et al.* [16] provide evidence supporting the involvement of virus-induced cytokines, in particular tumour necrosis factor- $\alpha$ , as mediators of senescence induction, suggesting that there may be multiple potential inducers of senescence in COVID-19.

These findings complement recent work published by LEE *et al.* [18] and CAMELL *et al.* [19] on this subject. LEE *et al.* [18] demonstrated increased markers of senescence in the airway mucosa of COVID-19 patients in addition to elevated concentrations of SASP factors in patient serum. An association of clinical case severity with high pro-inflammatory and pro-coagulant SASP factor levels (IL-6 and SERPINA3, respectively) and coagulation activity was also demonstrated and correlated *in vitro* with supernatant from virus-induced senescent cells promoting platelet activation, reduced clotting times and increased neutrophil extracellular trap formation, consistent with the pro-thrombotic phenotype seen clinically. Both LEE *et al.* [18] and CAMELL *et al.* [19] have also demonstrated improved outcomes with senolytic therapies including navitoclax and a combination of dasatinib plus quercetin, using *in vivo* models with both SARS-CoV-2 and a closely-related  $\beta$ -coronavirus. CAMELL *et al.* [19] focused particularly on an aged mouse model, establishing an increased senescent cell burden with age as a potential mechanism for the enhanced vulnerability of the elderly and frail to COVID-19.

In a novel finding, EVANGELOU *et al.* [2] also detail the potential implications of senescence on viral mutagenesis. They explain that senescent cells' ability to host the virus for longer periods increases the probability of host-mediated editing of the viral genome [20]. Building on earlier work that demonstrated high expression of APOBEC (apolipoprotein B mRNA-editing catalytic polypeptide-like) enzymes in senescent cells [21] and using bioinformatic analyses and next-generation sequencing of senescent cell progenies, they demonstrate the prominence of the APOBEC enzymes in the mutational signature of SARS-CoV-2 variants. Characterisation of the Omicron (B.1.1.529) variant identified the APOBEC signature as the main mutational profile, consistent with previous observations of a prominent role for APOBEC-mediated editing in the current pandemic [22]. Interestingly, EVANGELOU *et al.* [2] also observed significantly lower mutational burdens in oncogenic viruses including human papilloma virus and Epstein–Barr virus than in SARS-CoV-2 and HIV. Such insights into the mutagenesis of SARS-CoV-2 are of significant value as despite the positive impacts generated by COVID-19 vaccine development, the risk of further disruption and morbidity from new variants remains. New observations on viral mutagenesis in the context of this pandemic may therefore have significant implications for subsequent vaccination strategies.

Furthermore, it is also, as yet, not fully clear to what extent vaccine efficacy is achieved or maintained in clinically vulnerable groups, for example cancer patients [23], meaning that insights into mechanisms and therefore potential therapeutic targets remain important. The promising results of senolytic therapies *in vivo* continue to be explored in a number of clinical trials with some encouraging early results [24–26]. The particular promise of flavonoids such as fisetin and quercetin in recently published work relating to COVID-19 is noteworthy due to their low toxicity profile, as other senolytic agents such as the Bcl-2/Bcl-XL dual inhibitor, navitoclax, have been limited in clinical tolerability due to significant toxicities [27]. High rates of thrombocytopenia have been a particular concern with navitoclax use previously [27],

although modification using prodrugs and drug adaptation with proteolysis-targeting chimera technology have shown promise in reducing the incidence of thrombocytopenia *in vivo* [28, 29]. Platelet toxicity is of relevance in COVID-19 (and other coronaviruses) as mild thrombocytopenia is present in approximately 30–60% of cases, and cases of severe immune thrombocytopenia have been reported [30, 31]. Of note, LEE *et al.* [18] found that, in *in vivo* models emulating a severe COVID-19 phenotype, the animals treated with navitoclax had significantly worse outcomes in terms of clinical impairment and weight loss, whilst those treated with quercetin (in combination with the tyrosine kinase inhibitor dasatinib) displayed improved survival and clinical course.

In their recent review, KOHLI *et al.* [8] summarised key unanswered questions on the subject of virus-induced senescence, with two being of particular relevance here. First is the question of whether senolytics or SASP modulators (termed senomorphics or senostatics, such as rapamycin or metformin) could be used clinically in the setting of acute and chronic viral infections. Secondly, they also questioned the role of senescence in COVID-19 pathology and potential links to the higher mortality rates in older patients, building on the hypotheses proposed by NEHME *et al.* [7].

The work of EVANGELOU *et al.* [2] and others [16, 18, 19] contributes towards answering these questions, providing a significant contribution to understanding the role of senescence in the cytokine storm and severe multi-organ morbidity that have characterised severe clinical forms of COVID-19. The insights gleaned are valuable both in the current pandemic and for future pandemic preparedness, with first-generation senolytics already in clinical trials providing potential new therapeutic avenues. Challenges remain, and more refined tools to assess for the presence of senescence *in vivo* and in clinical settings are still required but, in conclusion, cellular senescence should be considered as a key factor and potential target in the pathogenesis of severe clinical forms of COVID-19, and the impact of senescence actively considered in other viral pathologies.

Conflict of interest: The authors have nothing to disclose.

## References

- 1 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Date last accessed: 25 May 2022. <https://covid19.who.int>
- 2 Evangelou K, Veroutis D, Paschalaki K, *et al.* Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. *Eur Respir J* 2022; 60: 2102951.
- 3 Gorgoulis V, Adams PD, Alimonti A, *et al.* Cellular senescence: defining a path forward. *Cell* 2019; 179: 813–827.
- 4 Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res* 1961; 25: 585–621.
- 5 Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. *Nat Rev Mol Cell Biol* 2014; 15: 482–496.
- 6 Di Micco R, Krizhanovsky V, Baker D, *et al.* Cellular senescence in ageing: from mechanisms to therapeutic opportunities. *Nat Rev Mol Cell Biol* 2021; 22: 75–95.
- 7 Nehme J, Borghesan M, Mackedenski S, *et al.* Cellular senescence as a potential mediator of COVID-19 severity in the elderly. *Aging Cell* 2020; 19: e13237.
- 8 Kohli J, Veenstra I, Demaria M. The struggle of a good friend getting old: cellular senescence in viral responses and therapy. *EMBO Rep* 2021; 22: e52243.
- 9 Baz-Martínez M, Da Silva-Álvarez S, Rodríguez E, *et al.* Cell senescence is an antiviral defense mechanism. *Sci Rep* 2016; 6: 37007.
- 10 Cohen J, D'Agostino L, Wilson J, *et al.* Astrocyte senescence and metabolic changes in response to HIV antiretroviral therapy drugs. *Front Aging Neurosci* 2017; 9: 281.
- 11 Cohen J, D'Agostino L, Tuzer F, *et al.* HIV antiretroviral therapy drugs induce premature senescence and altered physiology in HUVECs. *Mech Ageing Dev* 2018; 175: 74–82.
- 12 Sánchez-Díaz L, Espinosa-Sánchez A, Blanco J-R, *et al.* Senotherapeutics in cancer and HIV. *Cells* 2022; 11: 1222.
- 13 Liu PP, Blet A, Smyth D, *et al.* The science underlying COVID-19: implications for the cardiovascular system. *Circulation* 2020; 142: 68–78.
- 14 Nalbandian A, Sehgal K, Gupta A, *et al.* Post-acute COVID-19 syndrome. *Nat Med* 2021; 27: 601–615.
- 15 National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing COVID-19. NICE guideline [NG191]. Date last accessed: 24 May 2022. [www.nice.org.uk/guidance/ng191](http://www.nice.org.uk/guidance/ng191)
- 16 Tsuji S, Minami S, Hashimoto R, *et al.* SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response. *Nat Aging* 2022; 2: 115–124.

- 17 Bharat A, Querrey M, Markov NS, *et al.* Lung transplantation for patients with severe COVID-19. *Sci Transl Med* 2020; 12: eabe4282.
- 18 Lee S, Yu Y, Trimpert J, *et al.* Virus-induced senescence is a driver and therapeutic target in COVID-19. *Nature* 2021; 599: 283–289.
- 19 Camell CD, Yousefzadeh MJ, Zhu Y, *et al.* Senolytics reduce coronavirus-related mortality in old mice. *Science* 2021; 373: eabe4832.
- 20 Karakasiliotis I, Lagopati N, Evangelou K, *et al.* Cellular senescence as a source of SARS-CoV-2 quasispecies. *FEBS J* 2021; in press [<https://doi.org/10.1111/febs.16230>].
- 21 Venkatesan S, Angelova M, Puttick C, *et al.* Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. *Cancer Discov* 2021; 11: 2456–2473.
- 22 Ratcliff J, Simmonds P. Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution. *Virology* 2021; 556: 62–72.
- 23 Fendler A, de Vries EGE, GeurtsvanKessel CH, *et al.* COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. *Nat Rev Clin Oncol* 2022; 19: 385–401.
- 24 Di Pierro F, Iqtadar S, Khan A, *et al.* Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial. *Int J Gen Med* 2021; 14: 2807–2816.
- 25 Di Pierro F, Derosa G, Maffioli P, *et al.* Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. *Int J Gen Med* 2021; 14: 2359–2366.
- 26 Verdoorn BP, Evans TK, Hanson GJ, *et al.* Fisetin for COVID-19 in skilled nursing facilities: senolytic trials in the COVID era. *J Am Geriatr Soc* 2021; 69: 3023–3033.
- 27 Wyld L, Bellantuono I, Tchkonja T, *et al.* Senescence and cancer: a review of clinical implications of senescence and senotherapies. *Cancers* 2020; 12: 2134.
- 28 González-Gualda E, Pàez-Ribes M, Lozano-Torres B, *et al.* Galacto-conjugation of navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. *Aging Cell* 2020; 19: e13142.
- 29 He Y, Zhang X, Chang J, *et al.* Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. *Nat Commun* 2020; 11: 1996.
- 30 Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. *Pathobiology* 2021; 88: 15–27.
- 31 Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. *SN Compr Clin Med* 2020; 2: 2048–2058.